Development of a non invasive NGF-based therapy for alzheimer's disease

Current Alzheimer Research

Volumn 6, Issue 2, 2009, Pages 158-170

  Covaceuszach, Sonia ^a,c   Capsoni, Simona ^a,b,c   Ugolini, Gatsuella ^a,c   Spirito, F ^a   Vignone, D ^a,b   Cattaneo, Antonio ^b,d  

^a Lay Line Genomics SpA   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c Rotta Research Laboratorium   (Italy)

^d Rita Levi Montalcini Foundation   (Italy)

Author keywords

Intranasal delivery dosing mouse model therapeutic window; Long lasting cholinergic therapy; NGF mutein

Indexed keywords

HUMAN NERVE GROWTH FACTOR 61; MUTANT PROTEIN; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DISTRIBUTION; DRUG POTENCY; FOREBRAIN; GENE LINKAGE DISEQUILIBRIUM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NOCICEPTION; NON INVASIVE PROCEDURE; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ENGINEERING; SAFETY;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MODELS, MOLECULAR; MUTATION; NERVE GROWTH FACTOR; NEUROPSYCHOLOGICAL TESTS; RATS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; SEQUENCE ALIGNMENT; SURFACE PLASMON RESONANCE; TRANSFECTION;

EID: 64549141182     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787602870     Document Type: Article

References (47)

1. Levi-Montalcini R and Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116: 321-61 (1951).
2. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237: 1154-62 (1987).
3. Phelps CH, Gage FH, Growdon JH, Hefti F, Harbaugh R, Johnston MV, et al. Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol Aging 10: 205-7 (1989).
4. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83: 9231-5 (1986).
5. Molnar M, Tongiorgi E, Avignone E, Gonfloni S, Ruberti F, Domenici L, et al. The effects of anti-nerve growth factor monoclonal antibodies on developing basal forebrain neurons are transient and reversible. Eur J Neurosci 10: 3127-40 (1998).
6. Giacobini E. Cholinesterase in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorder's. In: Giacobini E. and Pepeu G, Eds. The Brain Cholinergic system in Health and Disease. Informa Healthcare, 235-264 (2006).
7. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT and Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-9 (1982).
8. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-8 (2005).
9. Bartus RT, Dean RL, 3rd, Beer B and Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-14 (1982).
10. Schliebs R and Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113: 1625-44 (2006).
11. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain choliner-gic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 20: 2589-601 (2000).
12. Capsoni S, Giannotta S and Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic antinerve growth factor antibodies. Mol Cell Neurosci 21: 15-28 (2002).
13. Origlia N, Capsoni S, Domenici L and Cattaneo A. Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice. J Alzheimers Dis 9: 59-68 (2006).
14. Sola E, Capsoni S, Rosato-Siri M, Cattaneo A and Cherubini E. Failure of nicotine-dependent enhancement of synaptic efficacy at Schaffer-collateral CA1 synapses of AD11 anti-nerve growth factor transgenic mice. Eur J Neurosci 24: 1252-64 (2006).
15. Capsoni S and Cattaneo A. On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell Mol Neurobiol 26: 619-33 (2006).
16. Cattaneo A. NGF processing and Alzheimer's disease neurodegeneration: too-little and too-much pro-NGF? Alzheimers Dement 2: S92 (2006).
17. Matrone C, Di Luzio A, Meli G, D'Aguanno S, Severini C, Ciotti MT, et al. Activation of the Amyloidogenic Route by NGF Deprivation Induces Apoptotic Death in PC12 Cells. J Alzheimers Dis 13: 81-96 (2008).
18. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9: 246-57 (1998).
19. Tuszynski MH, Thal L, Pay M, Salmon DP, UHS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551-5 (2005).
20. Chen XQ, Fawcett JR, Rahman YE, Ala TA and Frey IW. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J Alzheimers Dis 1: 35-44 (1998).
21. Capsoni S, Giannotta S and Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc Natl Acad Sci USA 99: 12432-7 (2002).
22. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 102: 3811-6 (2005).
23. Thorne RG and Frey WH, 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40: 907-46 (2001).
24. Aloe L, Alleva E and Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol Biochem Behav 73: 159-66 (2002).
25. Bimonte-Nelson HA, Singleton RS, Nelson ME, Eckman CB, Barber J, Scott TY, et al. Testosterone, but not nonaromatizable dihydrotestosterone, improves working memory and alters nerve growth factor levels in aged male rats. Exp Neurol 181: 301-12 (2003).
26. Sohrabji F, Miranda RC and Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 14: 459-71 (1994).
27. Cattaneo A, Rapposelli B and Calissano P. Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor. J Neurochem 50: 1003-10 (1988).
28. Covaceuszach S, Cattaneo A and Lamba D. Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody. Acta Crystallogr D Biol Crystallogr 57: 1307-9 (2001).
29. Rattenholl A, Ruoppolo M, Flagiello A, Monti M, Vinci F, Marino G, et al. Pro-sequence assisted folding and disulfide bond formation of human nerve growth factor. J Mol Biol 305: 523-33 (2001).
30. Cattaneo A, Capsoni S, Margotti E, Righi M, Kontsekova E, Pavlik P, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 19: 9687-97 (1999).
31. Hintz-Obertreis P, Krumwieh D and Seiler FR. Development of a rapid, highly sensitive, non-radioactive assay system for hematopoietic growth factors. Behring Inst Mitt 90: 99-103 (1991).
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63 (1983).
33. Greene LA and Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73: 2424-8 (1976).
34. Micera A, Lambiase A, Aloe L, Bonini S, Levi-Schaffer F and Bonini S. Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. Cytokine Growth Factor Rev 15: 411-7 (2004).
35. McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A and Blundell TL. New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature 354: 411-4 (1991).
36. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54: 1080-8 (2000).
37. Wiesmann C, Ultsch MH, Bass SH and de Vos AM. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401: 184-8 (1999).
38. Wehrman T, He X, Raab B, Dukipatti A, Blau H and Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 53: 25-38 (2007).
39. He XL and Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304: 870-5 (2004).
40. Diederichs K. Structural superposition of proteins with unknown alignment and detection of topological similarity using a six-dimensional search algorithm. Proteins 23: 187-95 (1995).
41. Chevalier S, Praloran V, Smith C, MacGrogan D, Ip NY, Yan-copoulos GD, et al. Expression and functionality of the trkA protooncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood 83: 1479-85 (1994).
42. Koliatsos VE, Nauta HJ, Clatterbuck RE, Holtzman DM, Mobley WC and Price DL. Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J Neurosci 10: 3801-13 (1990).
43. Kordower JH, Winn SR, Liu YT, Mufson EJ, Sladek JR, Jr., Hammang JP, et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 91: 10898-902 (1994).
44. Smith DE, Roberts J, Gage FH and Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 96: 10893-8 (1999).
45. Pradier P, Jalenques I, Dalle M, Reuling R, Despres G and Romand R. Distribution and metabolism patterns of plasma 7S-and beta-NGF in the adult male rat. J Physiol Paris 88: 273-7 (1994).
46. Pezet S and McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29: 507-38 (2006).
47. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 36: 244-6 (1994).